The only FDA action on this desk's regulatory sweep was a supplement, dated 27 August 2026, to an abbreviated new drug application (ANDA078786) for generic carvedilol. The record carries no indication, labelling or safety detail.
A supplement to a generic licence is usually administrative, such as a manufacturing or labelling update, and is not a new indication or a safety communication. Nothing in it changes urological prescribing.
It is a reminder of one practical interaction worth checking: men with lower urinary tract symptoms who take carvedilol, or another vasodilating beta-blocker, and are started on an alpha-blocker such as tamsulosin can have additive postural hypotension.
- No action is needed on this FDA record.
- When starting an alpha-blocker, check for beta-blockers and other antihypertensives.
- Advise taking the first alpha-blocker dose at bedtime and rising slowly.
- Ask older men about dizziness or falls at follow-up.
Why it matters
The regulatory sweep was quiet for urology, but alpha-blocker and beta-blocker co-prescription is common in older men.
Don't overread it
A licence supplement to a generic application is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free